Reneuron Share Discussion Threads

[fredd1eboy] 30/4/2017 20:36

Hi Algernon. Rene concentrating on glioblastoma multiforme. 4% survival 5 years. Death generally within 13 months. Exosone used as delivery vehicle for tailor made treatment. Guessing there's some other irons in the fire. Best wishes. Freddie

[algernon2] 30/4/2017 19:44

Really good stuff and interesting and just the right length for us to get a basic grip on the area but not get in so deep our brains explode.
Thanks Fredd1e.
If I remember correctly Reneuron have never said much re the area or what they are doing with it in any of their recent discussions.
Do we know anything of any particular areas of research RENE are doing re exosomes?
I may now top up at the next opportunity.

[fredd1eboy] 29/4/2017 16:15

For info....anyone interested in learning more about exosomes.

Series of 6 short videos on exosomes. Personally, I got enjoyed 1,2 and 6

[audigger] 26/4/2017 15:30

Think I may take the plunge and buy some of these. Could be a stressful journey but nothing ventured and all that...

[dennisbergkamp] 25/4/2017 12:14

;-) Like that.

I ran it past a well known Ophtha friend of mine and he said it could do very well, but its a punt. Figured, with the other products it has to, why not.

[fredd1eboy] 25/4/2017 10:57

Interesting list of posts. I cannot quite understand the drift but...
Best wishes to all.
Freddie

[yachtmaster2] 25/4/2017 10:52

Welcome on board buddy. Your as equally stupid as I am

[dennisbergkamp] 25/4/2017 10:20

Right, I'm in... Lets roll!

[rotors] 24/4/2017 21:16

"NOMADS have NO integrity; They suck blood and fees, stifeling the PIs"

Poor grammar and an even worse attempt at a pun.

[norbus] 24/4/2017 09:59

NOMADS have NO integrity; They suck blood and fees, stifeling the PIs

[rotors] 21/4/2017 17:17

Just to advise further that Stifel is RENE's NOMAD.
So they either have the inside track or a motive.
Cav Emp.

[rotors] 21/4/2017 16:55

Stifel
Target price 15p

'We value ReNeuron using a risk-adjusted NPV, suggesting a target
price of 15p. This places no value on the CRD or exosome
programmes – the exosome platform in particular is an exciting new
therapy field where ReNeuron is leading development, and is thus
likely to represent significant upside to our valuation in the event of a
deal or positive clinical trial results.
Risk to our investment case include clinical trial delays or negative
clinical trial results. ReNeuron will also be reliant on funding or
partnership deals once its current cash has expired in 2H18.'

[fredd1eboy] 21/4/2017 16:39

Guess you will have to look up Reneuron on either lse or iii sites to watch the proactive micheal hunt interview

[fredd1eboy] 21/4/2017 16:38

try again
[...]

[fredd1eboy] 21/4/2017 16:36

Micheal Hunt interview c/o mol iii site

[...]

[fredd1eboy] 21/4/2017 11:36

Goo news.....Motley Fool update...c/o oil prince iii site

[norbus] 21/4/2017 08:44

Shareholders have to keep the pressure on the management to keep it as honest as a
man with previous form can be to avoid selling the company cheap having been derisked
if they get there, with your money

Market not impressed

[dogwalker] 21/4/2017 08:31

Yes, there's a pulse.

[small crow] 21/4/2017 07:47

Good news.

[fredd1eboy] 20/4/2017 14:09

Thank you for your email and for your support as a shareholder of ReNeuron.

ReNeuron is aware of the video posted on social media and can confirm that the company was not involved in making it or had prior knowledge of its publication.

ReNeuron is the sponsor of the Phase I/II clinical trial in RP, a role in which it provides the drug product and finances the trial but is not directly involved with study participants.

Whilst it isn’t appropriate for ReNeuron to comment on the content of the video, please rest assured that ReNeuron will announce clinical data from the RP study, and other clinical programmes, in a timely manner through the conventional regulatory channel of RNS.

I would make the general point that the results of clinical trials are based on statistical analysis of all patients that complete a trial. A single patient, even in a small study, is not necessarily representative of the overall study results - that could only be known in hindsight. All trials, even late stage ones, have non-responders to the potential treatment being studied.

A further general point on early stage trials is that they are designed to inform later studies by establishing safety, tolerability and frequently dosage. For example, the Phase II part of the current Phase I/II trial in RP will be conducted at the highest safe dose in RP patients with a greater level of vision.

[norbus] 20/4/2017 13:44

where is the video? If it were misleading they would have gone to court to take it off circulation. The reply is significant. No denial ,disassociation with no defence. BAD

[dogwalker] 20/4/2017 09:38

The same applies to you too, stevedd. The answer to your question is 'yes they do'.

[dogwalker] 20/4/2017 09:36

Why do you ask stewart_25? Haven't you written your money off on this one yet?
But, if you really need to know, why not read some of the preceeding posts which people have helpfully contributed here?